β-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: A tissue microarray study

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 6, 2006, Pages 792-798

  Horvai, Andrew E ^a,c   Kramer, Miranda J ^b   O'Donnell, Richard ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; HYBRID PROTEIN; PHOSPHOPROTEIN; PROTEIN KINASE B; SYT SSX PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION X; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; SYNOVIAL SARCOMA; TISSUE MICROARRAY; CHEMISTRY; CHROMOSOME 18; CONNECTIVE TISSUE TUMOR; ENZYME IMMUNOASSAY; GENE TRANSLOCATION; GENETICS; LIMB; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SOFT TISSUE TUMOR; SURVIVAL RATE; X CHROMOSOME;

ADOLESCENT; ADULT; AGED; BETA CATENIN; CELL NUCLEUS; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, X; CYCLIN D1; EXTREMITIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33745034581     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol. 2001;32:257-263.
2. Saito T, Oda Y, Sakamoto A, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol. 2000;192:342-350.
3. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18:68-74.
4. Nelson JW, Nusse R, Convergence of Wnt, β-Catenin, and Cadherin pathways. Science. 2004;303:1483-1487.
5. Saito T, Oda Y, Tanaka K, et al. β-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J Pathol. 2001;195:222-228.
6. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422-426.
7. Kim SH, Cho NH, Tallini C, Dudas M, Lewis JJ, Cordon-Cardo C. Prognostic role of cyclin D1 in retroperitoneal sarcomas. Cancer. 2001;91(2):428-434.
8. Kim SH, Lewis JJ, Brennan MF, Woodruff JM, Dudas M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res. 1998;4:2377-2382.
9. Kennedy MM, Biddolph S, Lucas SB, et al. Cyclin D1 expression and HHV8 in Kaposi sarcoma. J Clin Pathol. 1999;52:569-573.
10. Sato H, Hasegawa T, Kanai Y, et al. Expression of cadherins and their undercoat proteins (alpha-, beta-, and gamma-catenins and p120) and accumulation of beta-catenin with no gene mutations in synovial sarcoma. Virchows Arch. 2001;438:23-30.
11. Antonescu CR, Leung DH, Dudas M, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol. 2000;156:977-983.
12. Xie Y, Skytting B, Nilsson G, et al. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res. 2002;62:3861-3867.
13. Xie Y, Skytting B, Nilsson G, et al. The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. Oncogene. 2002;21:5791-5796.
14. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499-3511.
15. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem. 2000;275:22916-22924.
16. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997;11:957-972.
17. Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418:823.
18. Porter DA, Krop IE, Nasser S, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001;61:5697-5702.
19. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036-1043.
20. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1:362-375.
21. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
22. Szymanska J, Serra M, Skytting B, et al. Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer. 1998;23:213-219.
23. Tarkkanen M, Huuhtanen R, Virolainen M, et al. Comparison of genetic changes in primary sarcomas and their pulmonary metastases. Genes Chromosomes Cancer. 1999;25:323-331.
24. Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19:525-534.
25. Weiss SW, Goldblum JR. Malignant soft tissue tumors of uncertain type. In: Enzinger and Weiss's Soft Tissue Tumors. 4th ed. Philadelphia, Pa: Mosby-Harcourt; 2001:1483-1509.
26. Horvai AE, Li L, Xu Z, Kramer MJ, Jablons DM, Treseler PA. Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2. Arch Pathol Lab Med. 2003;127:465-469.
27. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol. 2003;163:1449-1456.
28. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949.
29. Biegel JA, Conard K, Brooks JJ. Translocation (11;22)(p13;q12): primary change in intra-abdominal desmoplastic small round cell tumor. Genes Chromosomes Cancer. 1993;7:119-121.
30. Antonescu CR, Tschernyavsky SJ, Woodruff JM, Jungbluth AA, Brennan MF, Ladanyi M. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J Mol Diagn. 2002;4:44-52.
31. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162-165.
32. Panagopoulos I, Hoglund M, Mertens F, Mandahl N, Mitelman F, Aman P. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene. 1996;12:489-94.
33. Okamoto S, Hisaoka M, Daa T, Hatakeyama K, Iwamasa T, Hashimoto H. Primary pulmonary synovial sarcoma: a clinicopathologic, immunohistochemical, and molecular study of 11 cases. Hum Pathol. 2004;35:850-856.
34. Wang HL, Wang J, Xiao SY, et al. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin. Int J Cancer. 2002;101:301-310.